Related Experiment Video
Updated: Nov 6, 2025

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
Published on: March 17, 2014
Azithromycin Exhibits Activity Against Pseudomonas aeruginosa in Chronic Rat Lung Infection Model
Manoj Kumar1,2, Madhvi Rao1, Tarun Mathur1
1Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, India.
Abstract:
Pseudomonas aeruginosa forms biofilms in the lungs of chronically infected cystic fibrosis patients, which are tolerant to both the treatment of antibiotics and the host immune system. Normally, antibiotics are less effective against bacteria growing in biofilms; azithromycin has shown a potent efficacy in cystic fibrosis patients chronically infected with P. aeruginosa and improved their lung function. The present study was conducted to evaluate the effect of azithromycin on P. aeruginosa biofilm. We show that azithromycin exhibited a potent activity against P. aeruginosa biofilm, and microscopic observation revealed that azithromycin substantially inhibited the formation of solid surface biofilms. Interestingly, we observed that azithromycin restricted P. aeruginosa biofilm formation by inhibiting the expression of pel genes, which has been previously shown to play an essential role in bacterial attachment to solid-surface biofilm. In a rat model of chronic P. aeruginosa lung infection, we show that azithromycin treatment resulted in the suppression of quorum sensing-regulated virulence factors, significantly improving the clearance of P. aeruginosa biofilms compared to that in the placebo control. We conclude that azithromycin attenuates P. aeruginosa biofilm formation, impairs its ability to produce extracellular biofilm matrix, and increases its sensitivity to the immune system, which may explain the clinical efficacy of azithromycin in cystic fibrosis patients.
Insights
Azithromycin effectively inhibits Pseudomonas aeruginosa biofilm formation by targeting key genes and virulence factors. This action enhances bacterial clearance and may explain its clinical success in cystic fibrosis patients.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Pseudomonas aeruginosa biofilms in cystic fibrosis lungs are antibiotic and immune resistant.
- Azithromycin shows clinical efficacy in cystic fibrosis patients with chronic P. aeruginosa infections.
Purpose of the Study:
- To evaluate the effect of azithromycin on Pseudomonas aeruginosa biofilm formation and structure.
- To investigate the molecular mechanisms underlying azithromycin's anti-biofilm activity.
Main Methods:
- Microscopic observation of biofilm formation.
- Analysis of pel gene expression.
- In vivo rat model of chronic P. aeruginosa lung infection.
- Assessment of quorum sensing-regulated virulence factors.
Main Results:
- Azithromycin potently inhibited P. aeruginosa biofilm formation on solid surfaces.
- Azithromycin reduced the expression of pel genes essential for biofilm attachment.
- In vivo, azithromycin suppressed virulence factors and improved biofilm clearance in a rat model.
Conclusions:
- Azithromycin attenuates P. aeruginosa biofilm development and matrix production.
- Azithromycin increases bacterial susceptibility to the host immune system.
- These mechanisms likely contribute to azithromycin's therapeutic benefits in cystic fibrosis.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
06:43Studying Microbial Communities In Vivo: A Model of Host-mediated Interaction Between Candida Albicans and Pseudomonas Aeruginosa in the Airways
Published on: January 13, 2016